CEDAR KNOLLS, N.J., Jan. 31 EmisphereTechnologies, Inc. (Nasdaq: EMIS), announced today that it will host ateleconference on Thursday, February 7, at 10:00 AM EST. President and ChiefExecutive Officer Michael V. Novinski will discuss the company's emergingbusiness strategy. Emisphere is a biopharmaceutical company that focuses on aunique and improved delivery of therapeutic molecules and pharmaceuticalcompounds using its eligen(R) technology.
A live Webcast of the conference call can be accessed through thecompany's web site at www.emisphere.com. The live conference call dial-innumber is: 1-888-264-8952 (U.S. and Canada) or 1-913-312-0654 (International).In addition, an archive of the Webcast can be accessed through the same link;an audio replay of the call will be available following the conference call bycalling 1-888-203-1112 (U.S. and Canada) or 1-719-457-0820 (International).The conference replay PIN is 871428. A slide deck will be available on theEmisphere web site at the time of the call.
"Emisphere's investor base is a valued resource," said Michael V.Novinski, President and Chief Executive Officer of Emisphere Technologies,Inc. "Our teleconference will provide investors with a better understandingof where we are taking the company and what opportunities lie ahead."
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company that focuseson a unique and improved delivery of therapeutic molecules using its eligen(R)technology. These molecules and compounds could be currently available or indevelopment. Such molecules are usually delivered by injection; in many cases,their benefits are limited due to poor bioavailability, slow on-set of actionor variable absorption. The eligen(R) technology can be applied to the oralroute of administration as well other delivery pathways, such as buccal,rectal, inhalation, intra-vaginal or transdermal. The Web site iswww.emisphere.com.
Safe Harbor Statement Regarding Forward-Looking Statements
The statements in this release and oral statements made by representativesof Emisphere relating to matters that are not historical facts (includingwithout limitation those regarding future performance or financial results,the timing or potential outcomes of research collaborations or clinicaltrials, any market that might develop for any of Emisphere's productcandidates and the sufficiency of Emisphere's cash and other capitalresources) are forward-looking statements that involve risks anduncertainties, including, but not limited to, the likelihood that actualperformance or results could materially differ, that future research willprove successful, the likelihood that any product in the research pipelinewill receive regulatory approval in the United States or abroad, the abilityof Emisphere and/or its partners to develop, manufacture and commercializeproducts using Emisphere's drug delivery technology, or Emisphere's ability tofund such efforts with or without partners. Emisphere undertakes no obligationto update any of these statements. Readers are cautioned not to place unduereliance on these forward-looking statements, which speak only as to the datehereof. Accordingly any forward-looking statements should be read inconjunction with the additional risks and uncertainties detailed inEmisphere's filings with the Securities and Exchange Commission, includingthose factors discussed under the caption "Risk Factors" in Emisphere's AnnualReport on Form 10-K (file no. 000-17758) filed on March 6, 2007, and ourQuarterly Report on Form 10-Q for the quarter ended March 31, 2007, filed onMay 7, 2007 (file no. 000-17758) and for the quarter ended June 30, 2007,filed on August 7, 2007 (file No. 000-17758).
SOURCE Emisphere Technologies, Inc.